Bitcoin (BTC) ve Altcoinlerin 2025 Karnesi Açıklandı! Ethereum (ETH) ve İki Altcoin 2025’in Gözdesi Oldu!

The post Is Doge Losing Steam As Traders Choose Pepeto For The Best Crypto Investment? appeared on BitcoinEthereumNews.com. Crypto News 17 September 2025 | 17:39 Is dogecoin really fading? As traders hunt the best crypto to buy now and weigh 2025 picks, Dogecoin (DOGE) still owns the meme coin spotlight, yet upside looks capped, today’s Dogecoin price prediction says as much. Attention is shifting to projects that blend culture with real on-chain tools. Buyers searching “best crypto to buy now” want shipped products, audits, and transparent tokenomics. That frames the true matchup: dogecoin vs. Pepeto. Enter Pepeto (PEPETO), an Ethereum-based memecoin with working rails: PepetoSwap, a zero-fee DEX, plus Pepeto Bridge for smooth cross-chain moves. By fusing story with tools people can use now, and speaking directly to crypto presale 2025 demand, Pepeto puts utility, clarity, and distribution in front. In a market where legacy meme coin leaders risk drifting on sentiment, Pepeto’s execution gives it a real seat in the “best crypto to buy now” debate. First, a quick look at why dogecoin may be losing altitude. Dogecoin Price Prediction: Is Doge Really Fading? Remember when dogecoin made crypto feel simple? In 2013, DOGE turned a meme into money and a loose forum into a movement. A decade on, the nonstop momentum has cooled; the backdrop is different, and the market is far more selective. With DOGE circling ~$0.268, the tape reads bearish-to-neutral for the next few weeks: hold the $0.26 shelf on daily closes and expect choppy range-trading toward $0.29–$0.30 where rallies keep stalling; lose $0.26 decisively and momentum often bleeds into $0.245 with risk of a deeper probe toward $0.22–$0.21; reclaim $0.30 on a clean daily close and the downside bias is likely neutralized, opening room for a squeeze into the low-$0.30s. Source: CoinMarketcap / TradingView Beyond the dogecoin price prediction, DOGE still centers on payments and lacks native smart contracts; ZK-proof verification is proposed,…

The post CEO Sandeep Nailwal Shared Highlights About RWA on Polygon appeared on BitcoinEthereumNews.com. Polygon CEO Sandeep Nailwal highlighted Polygon’s lead in global bonds, Spiko US T-Bill, and Spiko Euro T-Bill. Polygon published an X post to share that its roadmap to GigaGas was still scaling. Sentiments around POL price were last seen to be bearish. Polygon CEO Sandeep Nailwal shared key pointers from the Dune and RWA.xyz report. These pertain to highlights about RWA on Polygon. Simultaneously, Polygon underlined its roadmap towards GigaGas. Sentiments around POL price were last seen fumbling under bearish emotions. Polygon CEO Sandeep Nailwal on Polygon RWA CEO Sandeep Nailwal highlighted three key points from the Dune and RWA.xyz report. The Chief Executive of Polygon maintained that Polygon PoS was hosting RWA TVL worth $1.13 billion across 269 assets plus 2,900 holders. Nailwal confirmed from the report that RWA was happening on Polygon. The Dune and https://t.co/W6WSFlHoQF report on RWA is out and it shows that RWA is happening on Polygon. Here are a few highlights: – Leading in Global Bonds: Polygon holds 62% share of tokenized global bonds (driven by Spiko’s euro MMF and Cashlink euro issues) – Spiko U.S.… — Sandeep | CEO, Polygon Foundation (※,※) (@sandeepnailwal) September 17, 2025 The X post published by Polygon CEO Sandeep Nailwal underlined that the ecosystem was leading in global bonds by holding a 62% share of tokenized global bonds. He further highlighted that Polygon was leading with Spiko US T-Bill at approximately 29% share of TVL along with Ethereum, adding that the ecosystem had more than 50% share in the number of holders. Finally, Sandeep highlighted from the report that there was a strong adoption for Spiko Euro T-Bill with 38% share of TVL. He added that 68% of returns were on Polygon across all the chains. Polygon Roadmap to GigaGas In a different update from Polygon, the community…

– Primary endpoint met in both trials – – Bepirovirsen demonstrated a statistically significant and clinically meaningful functional cure rate – – Chronic hepatitis